NYSE:SYK

Stryker - SYK Stock Forecast, Price & News

$272.90

-10.24 (-3.62%)

(As of 02/6/2023 02:03 PM ET)

Add

Compare

Today's Range: $272.50
▼
$281.16
50-Day Range: $227.20
▼
$283.14
52-Week Range: $188.84
▼
$284.00

Volume: 816,446 shs
Average Volume: 1.51 million shs
Market Capitalization: $103.27 billion

P/E Ratio: 44.23
Dividend Yield: 1.06%
Price Target: $271.32

Institutional Ownership

Stryker MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.65 Rating Score
Upside/Downside: 0.6% Downside
$271.32 Price Target
Short Interest: Healthy
1.60% of Float Sold Short
Dividend Strength: Strong
Based on Four Factors
Sustainability: -0.95
Upright™ Environmental Score
News Sentiment: 0.56
Based on 56 Articles This Week
Insider Trading: Selling Shares
$19.15 M Sold Last Quarter
Proj. Earnings Growth: 10.17%
From $10.03 to $11.05 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

3.15 out of 5 stars

Medical Sector

16th out of 1,027 stocks

Surgical & Medical Instruments Industry

2nd out of 105 stocks

2.3

Analyst's Opinion

Consensus Rating
Stryker has received a consensus rating of Buy. The company's average rating score is 2.65, and is based on 13 buy ratings, 7 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $271.32, Stryker has a forecasted downside of 0.6% from its current price of $273.07.
Amount of Analyst Coverage
Stryker has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

5.0

Short Interest

Percentage of Shares Shorted
1.60% of the float of Stryker has been sold short.
Short Interest Ratio / Days to Cover
Stryker has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Stryker has recently decreased by 8.32%, indicating that investor sentiment is improving significantly.

4.2

Dividend Strength

Dividend Yield
Stryker pays a meaningful dividend of 1.06%, higher than the bottom 25% of all stocks that pay dividends.
Dividend Growth
Stryker has been increasing its dividend for 29 years.
Dividend Coverage
The dividend payout ratio of Stryker is 48.62%. This payout ratio is at a healthy, sustainable level, below 75%.
Dividend Sustainability
Based on earnings estimates, Stryker will have a dividend payout ratio of 27.15% next year. This indicates that Stryker will be able to sustain or increase its dividend.

4.2

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Stryker has received a 60.46% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Neurostimulators", "Protective clothing", "Synthetic bone grafts", "Surgery simulation software", "Medical laboratory equipment", and "Bone cement" products. See details.
Environmental Sustainability
The Environmental Impact score for Stryker is -0.95.

3.6

News and Social Media Coverage

News Sentiment
Stryker has a news sentiment score of 0.56. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.46 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 56 news articles for Stryker this week, compared to 6 articles on an average week.
Search Interest
26 people have searched for SYK on MarketBeat in the last 30 days. This is an increase of 53% compared to the previous 30 days.
MarketBeat Follows
20 people have added Stryker to their MarketBeat watchlist in the last 30 days. This is an increase of 25% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Stryker insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $19,150,115.00 in company stock.
Percentage Held by Insiders
Only 6.50% of the stock of Stryker is held by insiders.
Percentage Held by Institutions
77.10% of the stock of Stryker is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

2.5

Earnings and Valuation

Earnings Growth
Earnings for Stryker are expected to grow by 10.17% in the coming year, from $10.03 to $11.05 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Stryker is 44.26, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 137.80.
Price to Earnings Ratio vs. Sector
The P/E ratio of Stryker is 44.26, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 107.31.
Price to Earnings Growth Ratio
Stryker has a PEG Ratio of 2.90. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Stryker has a P/B Ratio of 6.22. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Stryker (NYSE:SYK) Stock

Stryker Corp. operates as a medical technology company. It operates through the following segments: Orthopaedics & Spine and MedSurg & Neurotechnology. The Orthopaedics & Spine segment provides implants for use in total joint replacements, such as hip, knee, and shoulder, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical and thoracolumbar systems that are used in spinal injury, complex spine and degenerative therapies. The MedSurg and Neurotechnology segment offers surgical equipment, patient & caregiver safety technologies, and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. This segment also provides neurotechnology products, which include products used for minimally invasive endovascular techniques, products for brain and open skull based surgical procedures, orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products, minimally invasive products fo

Receive SYK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Stryker and its competitors with MarketBeat's FREE daily newsletter.

SYK Stock News Headlines

February 5, 2023 | americanbankingnews.com

Barclays Boosts Stryker (NYSE:SYK) Price Target to $283.00

February 5, 2023 | americanbankingnews.com

FY2023 Earnings Forecast for Stryker Co. (NYSE:SYK) Issued By Jefferies Financial Group

February 6, 2023 | Wall Street Watch Dogs (Ad)

The #1 Energy Stock to Buy

The next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…

February 5, 2023 | americanbankingnews.com

Brokers Offer Predictions for Stryker Co.'s FY2023 Earnings (NYSE:SYK)